SEC Form 10-Q filed by ALX Oncology Holdings Inc.
$ALXO
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2024 | $10.00 → $14.00 | Buy → Hold | Stifel |
| 12/8/2023 | $8.00 → $18.00 | Hold → Buy | Jefferies |
| 3/1/2022 | $60.00 → $36.00 | Buy | Stifel |
| 12/22/2021 | $65.00 → $25.00 | Buy → Hold | Jefferies |
| 9/30/2021 | $106.00 | Buy | Stifel |
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
SC 13G/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
SC 13G - ALX ONCOLOGY HOLDINGS INC (0001810182) (Subject)
Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial populationIn the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR of 54.8% vs. 23.1% in the control, suggesting HER2-expression strongly correlates with evorpacept efficacy and validating its mechanism of actionCompany to host conference call and
Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2-positive gastric cancer. To access the live conference call, please dial (800) 715-9871 (U.S./Canada) or +44.800.260.6466 (internationally), Conference ID 9637001. To access the live a
Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate ("ADC"), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology ("ASCO")
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Buy and maintains $25 price target.
ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today presented data from its Phase 1 ASPEN-07 clinical trial in a poster presentation (abstract #4575) at the 2024 American Society of Cancer Oncology (“ASCO”) Annual Meeting being held in Chicago from May 31-June 4, 2024. These findings represent the first evorpacept combination data with an ADC from ASPEN-07’s ongoing, open-label, single-arm, clinical trial of evorpacept in combination with PADCEV (enfortumab vedotin or “EV”) in patients with locally advanced or metastatic urothelial cancer (“la/m UC”). Evorpacept is a
Cantor Fitzgerald analyst Li Watsek reiterates ALX Oncology Holdings (NASDAQ:ALXO) with a Overweight.
10-Q - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)
8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)
8-K - ALX ONCOLOGY HOLDINGS INC (0001810182) (Filer)
4/A - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today announced that management will participate in two upcoming investor conferences. 2024 UBS Global Healthcare ConferenceFormat: Fireside chat with analyst, Trung Huynh, and 1x1 meetingsDate: Tuesday, November 12Time: 3:30 PM PSTLocation: Rancho Palos Verdes, CAWebcast link: Available here 2024 Jefferies London Healthcare ConferenceFormat: Fireside chat with analyst, Michael Yee, and 1x1 meetingsDate: Tues
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer in new ways and extend patients' lives, today announced that results from a Phase 1b/2 combination trial evaluating ALX Oncology's evorpacept in combination with Jazz Pharmaceuticals' zanidatamab in HER2-positive and HER2-low metastatic breast cancer have been accepted for a poster spotlight presentation at the San Antonio Breast Cancer Symposium (SABCS), which will be held in San Antonio, Texas, from December 10-13, 2024. The Phase 1b/2 clinical tr
SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today that management will participate in the 2024 Cantor Fitzgerald Global Healthcare Conference being held in New York City on September 17 – 19, 2024. Format: Fireside chat with analyst, Li Watsek and 1x1 meetingsDate: Tuesday, September 17, 2024 Time: 1:55 PM ET Webcast link: Available here The live webcast of the fireside chat can be accessed by visiting the Investors section of ALX Oncology's website at Events under the News and Events tab.
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
4 - ALX ONCOLOGY HOLDINGS INC (0001810182) (Issuer)
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the second quarter ended June 30, 2024, and provided a corporate update. "Our team continues to make significant progress in the advancement of our evorpacept development pipeline across multiple oncology indications," said Jason Lettmann, Chief Executive Officer of ALX Oncology. "Data readouts across our Phase 1 and 2 clinical trials highlight the potential of evorpacept as a disruptive therapy in combination with anti
- Dr. Sandler brings more than 30 years of experience and leadership in oncology and drug development - - Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., will leave board to focus on ALX leadership responsibilities as Company's clinical program advances - SOUTH SAN FRANCISCO, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology" or "the Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced today the appointment of Alan Sandler, M.D., to its Board of Directors effective August 5, 2024. Dr. Sandler is a distinguished leader in oncology and drug development with over 30 years of e
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update. "We entered the quarter with a great deal of momentum having achieved a key validating development milestone for our platform asset evorpacept in Q4 2023 by reporting positive results in a prespecified randomized interim analysis of ASPEN-06's Phase 2 clinical trial in advanced HER2-positive gastric/GEJ cancer, becoming the first CD47 blocker to demon
Stifel downgraded ALX Oncology from Buy to Hold and set a new price target of $14.00 from $10.00 previously
Jefferies upgraded ALX Oncology from Hold to Buy and set a new price target of $18.00 from $8.00 previously
Stifel reiterated coverage of ALX Oncology Holdings with a rating of Buy and set a new price target of $36.00 from $60.00 previously